Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?

Answer from: Medical Oncologist at Community Practice

The hormone receptor-positive, HER2-positive (HR+/HER2+) breast cancer subtype is a distinct clinical entity from hormone receptor-negative, HER2-positive (HR−/HER2+) breast cancer. Moreover, there is heterogeneity among HR+/HER2+ tumors. The main oncogenic driver may vary among HR+/HER2+ pati...

Comments

Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital
Dr. @Copur, Patients with metastatic HER2+ ...

Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Thank you for the query, @Ayesha. The ER and HER2 ...

Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital
That’s very helpful. Thank you Dr. @Copur.&n...

Answer from: Medical Oncologist at Academic Institution

As opposed to combining hormonal therapies with HER2-targeted therapies that are intended to block signaling through the HER2 pathway, such as trastuzumab or the combination of trastuzumab and pertuzumab, whether administered in place of or after a course of chemotherapy combined with those HER2-tar...

Please select the option that best describes you:

Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?

Related Questions